The team at EvergreenHealth Women’s Specialty Care, Gynecology treats complex conditions, like endometriosis and fibroids. Sponsored by EvergreenHealth.

ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. Click here to read an analysis of IBRX stock now.

Early radical cystectomy can be beneficial and should be performed in patients with refractory T1 tumors or carcinoma in situ before progression to muscle invasion. In this Review I present an ...

The market for endometriosis treatment is projected to attain a value of US$ 3.1 billion by 2034. According to Transparency ...

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi ...

The US Food and Drug Administration (FDA) has granted priority review to AstraZeneca's supplemental biologics licence ...

AstraZeneca’s Imfinzi (durvalumab) has been granted Priority Review by the FDA for the treatment of muscle-invasive bladder cancer (MIBC), pote ...

US FDA grants priority review status to AstraZeneca’s sBLA for Imfinzi to treat patients with muscle-invasive bladder cancer: Cambridge, UK Saturday, December 7, 2024, 09:00 Hrs ...

Radical cystectomy (RC) is a morbid operation with a high rate of perioperative complications. If patients survive their cancer, long-term complications significantly impact their quality of life. Dr.

Partial and radical cystectomy offer comparable oncologic outcomes in well-selected patients with muscle-invasive bladder cancer, according to study findings presented at the 2024 annual meeting of ...

Patients found to have positive lymph nodes after robotic radical cystectomy for muscle-invasive bladder cancer may benefit from treatment de-escalation if they have undetectable circulating tumor DNA ...

Durvalumab (Imfinzi) has received Priority Review from the FDA for muscle-invasive bladder cancer (MIBC). Backed by positive ...